{
  "id": 5433,
  "text": "J Clin Oncol 2018 36.Available at: https://meetinglibrary.asco.org/record/160523/abstract.252.Monk BJ, Sill MW, Burger RA, et al.Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol 2018 36.Available at: https://meetinglibrary.asco.org/record/160523/abstract.252.Monk BJ, Sill MW, Burger RA, et al.Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "贝伐单抗是一种抗血管生成药物，在治疗持续性或复发性宫颈鳞状细胞癌方面具有显著效果。根据相关研究表明，贝伐单抗可以通过抑制肿瘤血管的形成，降低肿瘤的生长速度，从而延长患者的无进展生存期。在宫颈鳞状细胞癌的治疗中，贝伐单抗通常与其他化疗药物联合使用，以提高治疗效果。这种联合治疗方案可以进一步改善患者的总体生存率，并减轻癌症相关症状，为患者提供更好的生活质量管理。",
  "query": "在治疗持续性或复发性宫颈鳞状细胞癌方面，贝伐单抗的应用效果如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗持续性或复发性宫颈鳞状细胞癌方面，贝伐单抗的应用效果如何？\n\n<reference text>: J Clin Oncol 2018 36.Available at: https://meetinglibrary.asco.org/record/160523/abstract.252.Monk BJ, Sill MW, Burger RA, et al.Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "贝伐单抗是一种抗血管生成药物，在治疗持续性或复发性宫颈鳞状细胞癌方面具有显著效果。根据相关研究表明，贝伐单抗可以通过抑制肿瘤血管的形成，降低肿瘤的生长速度，从而延长患者的无进展生存期。在宫颈鳞状细胞癌的治疗中，贝伐单抗通常与其他化疗药物联合使用，以提高治疗效果。这种联合治疗方案可以进一步改善患者的总体生存率，并减轻癌症相关症状，为患者提供更好的生活质量管理。"
}